Evidence map›Paper›PMID 41413729›Full record

ArticleEuropean journal of clinical investigation2026

HDL function and composition in atherothrombotic cardiovascular disease with very high HDL-C.

Teresa Padro, Natàlia Muñoz-García, Marta Fanlo-Maresma, Virginia Esteve-Luque, Paula Cabré-Fernandez, Gemma Vilahur, Antoni Riera-Mestre, Lina Badimon, Xavier Pintó

Abstract read
In one paragraph

Article in European journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Teresa PadroInstitut Recerca Sant Pau, Barcelona, Spain.ORCID https://orcid.org/0000-0003-1921-954X
Natàlia Muñoz-GarcíaInstitut Recerca Sant Pau, Barcelona, Spain.ORCID https://orcid.org/0000-0002-2982-8982
Marta Fanlo-MaresmaLipids and Vascular Risk Unit, Internal Medicine Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.
Virginia Esteve-LuqueLipids and Vascular Risk Unit, Internal Medicine Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.
Paula Cabré-FernandezInstitut Recerca Sant Pau, Barcelona, Spain.
Gemma VilahurInstitut Recerca Sant Pau, Barcelona, Spain.ORCID https://orcid.org/0000-0002-2828-8873
Antoni Riera-MestreLipids and Vascular Risk Unit, Internal Medicine Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.
Lina BadimonInstitut Recerca Sant Pau, Barcelona, Spain.
Xavier PintóLipids and Vascular Risk Unit, Internal Medicine Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.ORCID https://orcid.org/0000-0002-2216-2444

Funding

Agencia Estatal de Investigación AEI/10.13039/501100011033-[PID2019-107160RB-I00]Agencia Estatal de Investigación PID2021-128891OB-I00Fundació la Marató de 3Cat 202329-10Institute of Health Carlos III (ISCIII) EC10-142Instituto de Salud Carlos III (ISCIII) with Next Generation EU funds from the Recovery and Resilience Mechanism (RRM) Program PMP22/00108
6 · The paper itself

Abstract

backgroundEmerging evidence demonstrates a J-shaped relationship between HDL-C levels and atherosclerotic cardiovascular disease (ASCVD) with very high HDL-C concentrations paradoxically associated with increased ASCVD events. This study aims to determine whether individuals with very high HDL-C (>80 mg/dL) and ASCVD exhibit altered HDL composition and impaired HDL functionality.

methodsWe investigated the HDL profile and functionality in 49 subjects (mean age: 62 ± 2 years, 83% female) with very high HDL-C levels (>80 mg/dL), including 23 with ASCVD. All ASCVD patients and 46% of those without ASCVD (non-ASCVD) were on lipid-lowering treatment.

resultsPlasma atherogenic lipoprotein-cholesterol levels were significantly lower in ASCVD patients than in those without ASCVD, despite matched HDL-C levels. CEC differences were evident after tertile stratification, with ASCVD participants overrepresented in the lowest tertile and showing lower median [IQR] CEC than non-ASCVD (p = 0.030). Total radical-trapping antioxidative potential showed no significant group differences in HDL ability to inhibit copper-induced LDL oxidation. However, basal HDL oxidative level was significantly higher in the ASCVD compared with the non-ASCVD group (p = 0.007). Inflammatory glycoproteins were inversely associated with CEC and HDL-C levels in ASCVD patients, but not in non-ASCVD patients. By NMR, mean HDL particle diameter did not differ between groups, yet ASCVD patients had fewer percent of large HDL particles compared to the non-ASCVD (0.84 ± 0.02% vs. 0.91 ± 0.02%; p = 0.034) and a trend toward more small particles. HDL-C content increased with particle size in ASCVD (p = 0.008; r = 0.531), but not in non-ASCVD, while HDL-TG levels did not differ across tertiles. Functional cell-based assays showed attenuated endothelial proliferation (normalized Cell-Index) in ASCVD compared with non-ASCVD, most evident in the largest HDL particle tertile.

conclusionsThese findings suggest that HDL functionality and particle distribution may offer more clinically relevant insights into cardiovascular risk than plasma HDL-C concentrations alone, particularly in individuals with very high HDL-C levels.

Indexed as

AtherosclerosisCardiovascular DiseasesCholesterol, HDLAgedFemaleHumansMaleMiddle AgedCholesterol, HDLatherothrombotic cardiovascular diseasecholesterol effluxhigh‐density lipoproteinsinflammationstatins

Identifiers

PMID41413729
PMCPMC12827843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.